On November 19, Beam Therapeutics, Inc. rose 5.07% in Regular Trading, trading at $22.04 per share, with turnover of $10.8721 million.
The move followed continued market attention on positive progress for the company’s sickle cell disease candidate risto-cel, which has remained the central catalyst in recent trading.
Background context shows the BEACON 1/2 trial for risto-cel met primary efficacy and safety endpoints and achieved all secondary endpoints, with the company planning to submit a BLA to the FDA before year-end. While Beam Therapeutics, Inc. previously reported a quarterly loss of $1.28 per share, wider than the $1.15 loss expected, and recent analyst consensus for next year revenue turned more conservative, the clinical milestone continues to support investor focus on the commercialization path of its base editing platform.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments